Select publications

Boccardo F et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: Updated results of a multicentric trial. Eur Urol 2002;42(5):481-90. Abstract

Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300. Abstract

Byar DP, Corle DK. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7:165–70. Abstract

Carswell CI, Figgitt DP. Bicalutamide: In early-stage prostate cancer. Drugs. 2002;62(17):2473-81. Abstract

Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med 1999;341(24):1837–8. No abstract available

Granfors T et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol 1998;159(6):2030–4. Abstract

Grimm MO et al. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 2002;41(6):628-34; discussion 634. Abstract

Iversen P et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early nonmetastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol 2002;42(3):204-11. Abstract

Iversen P. Antiandrogen monotherapy: Indications and results. Urology 2002;60(3 Suppl 1):64-71. Abstract

Mazeman E, Bertrand P. Early versus delayed hormonal therapy in advanced prostate cancer. Eur Urol 1996;30 Suppl 1:40-3;discussion 49. Abstract

Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8. Abstract

Milbank AJ et al. Hormonal therapy for prostate cancer: Primum non nocere. Urology 2002;60(5):738-41. Full text

Naito S. Androgen deprivation in combination with radical prostatectomy for localized prostate cancer. Int J Urol 2001;8(7):S19-21. Abstract

Pilepich MV et al. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50(5):1243-52. Abstract

Pilepich MV et al. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proceedings of the American Society for Clinical Oncology (ASCO) Meeting, Los Angeles, CA (abstract). J Clin Oncol 1998;17(suppl):308a. Abstract

Pilepich MV et al. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15(3): 1013–21. Abstract

Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 1997;79(2):235-46. Abstract

Schroder FH. Endocrine treatment of prostate cancer—recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. BJU Int 1999;83(2):161-70. Review. No abstract available.

Soloway MS. Timing of androgen deprivation for prostate cancer: Benefits versus side effects — A patient-physician dialogue. Urology 2002;60:735-737. No abstract available

Soloway MS et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167(1):112-6. Abstract

Studer UE et al. Immediate vs deferred hormonal therapy for prostate cancer patients not suitable for curative local treatment (abstract). J Urol 2002;167:303. Abstract

Walsh PC et al. A structured debate: Immediate versus deferred androgen suppression in prostate cancer—evidence for deferred treatment. J Urol 2001;166(2): 508–16. Abstract

Zagars GK et al. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 2001;58(2):233–9. Abstract

Zincke H et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001;166(6):2208–15. Abstract

Home

Editor’s Note

Mark S Soloway, MD
    - Select publications

Richard Stock, MD
    - Select publications

Mitchell Benson, MD
    - Select publications

Editor's Office